Abstract
Advancing drug development for airway diseases beyond the established mechanisms and symptomatic therapies requires redefining the classifications of airway diseases, considering systemic manifestations, developing new tools and encouraging collaborations.
MeSH terms
-
Animals
-
Anti-Asthmatic Agents / therapeutic use
-
Asthma / diagnosis
-
Asthma / drug therapy
-
Asthma / epidemiology
-
Drug Discovery / trends*
-
Humans
-
Lung Diseases / diagnosis
-
Lung Diseases / drug therapy*
-
Lung Diseases / epidemiology
-
Pulmonary Disease, Chronic Obstructive / diagnosis
-
Pulmonary Disease, Chronic Obstructive / drug therapy
-
Pulmonary Disease, Chronic Obstructive / epidemiology